Appointment Letter for Executive Vice President, International Markets Commercial – Mark Sabag and Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. confirms Mark Sabag's appointment as Executive Vice President, International Markets Commercial, effective August 15, 2021. His compensation and other employment terms remain unchanged and are governed by his existing employment agreement. The letter expresses confidence in his continued contribution to the company's strategic goals.
Exhibit 10.25
Private and Confidential
July 27, 2021
To: Mark Sabag
Teva Global ID: 31507
Dear Mark,
Congratulations on your appointment as Executive Vice President, International Markets Commercial.
Effective Date: August 15, 2021
Your compensation will remain the same as prior to your appointment and the terms shall be as determined in your current employment agreement.
We strongly believe in the company and in your contribution to its success. We look forward to your continued commitment towards Teva’s short and long-term strategic goals.
Sincerely,
Kåre Schultz
President and Chief Executive Officer
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi’a St., Tel Aviv ###-###-#### Israel | www.tevapharm.com
